Chinese manufacturer of peptide active pharmaceutical ingredients used in diabetes, growth-hormone and other injectable drugs.
Chinese manufacturer of peptide active pharmaceutical ingredients used in diabetes, growth-hormone and other injectable drugs.
In one line: A small Chinese peptide-API supplier.
Moat: narrow (process know-how, regulatory licence). Peptide synthesis and purification know-how plus regulatory filings are costly to replicate quickly.
Headquarters: China · Employees: 2,360
Size Sinopep-Allsino Bio Pharmaceutical (688076.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.25B, the 1784th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥26.42 on 18 Nov 2026.
Performance Over six months the shares fell 15.6%, against -17.3% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 20 in its peer set.
Growth Revenue grew 14.1% over the last twelve months (peer median +1.8%); the operating margin is 18.6% (peer median -2.1%).
Valuation It trades at 11.9× forward earnings against a peer median of 21.3× (3rd cheapest of 10).
Price implies For today's price to make sense, revenue must grow about 3% a year for seven years (Req g). Recent delivered growth is +28%, so the hurdle is -24 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 4.0 points above its cost of capital (6.1% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.16B | CN¥1.94B | CN¥1.62B | CN¥1.03B | CN¥642M |
| Revenue growth | — | +20% | +57% | +61% | — |
| Gross profit | CN¥1.42B | CN¥1.14B | CN¥1.04B | CN¥575M | CN¥330M |
| EBITDA | n/a | CN¥762M | CN¥670M | CN¥324M | CN¥176M |
| Net income | CN¥223M | CN¥332M | CN¥404M | CN¥163M | CN¥129M |
| Free cash flow | CN¥156M | -CN¥684M | -CN¥689M | -CN¥308M | -CN¥408M |
| Capital expenditure | CN¥856M | CN¥1.37B | CN¥1.09B | CN¥661M | CN¥438M |
| Total debt | CN¥3.16B | CN¥2.87B | CN¥1.79B | CN¥1.01B | CN¥384M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | $1.25B | -16% | +14% | 19% | 11.9× | 3.4% |
| Bachem BANB.SW | $7.06B | 0% | +5% | 19% | 32.4× | n/a |
| PolyPeptide PPGN.SW | $1.61B | +7% | +22% | 7% | 52.1× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688076.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.7% | -5.1% | 9th lowest of 20 |
| 6-month return | -15.6% | -17.3% | 10th highest of 20 |
| Distance from 52-week high | -35.8% | -41.4% | 8th highest of 20 |
| Revenue growth (TTM) | +14.1% | +1.8% | 5th highest of 16 |
| Operating margin | 18.6% | -2.1% | 3rd highest of 16 |
| Forward P/E | 11.9× | 21.3× | 3rd cheapest of 10 |
| Growth the price implies (Req g, 7 yrs) | 3.4% | 2.5% | 3rd most demanding of 6 |
| Growth delivered (Del g) | +27.9% | -1.3% | highest of 6 |
| Hurdle (Req g minus delivered) | -24.5 pp | +1.0 pp | least demanding of 6 |
| ROIC minus cost of capital | +4.0 pp | -9.0 pp | 2nd highest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.25B | -16% | +14% | 19% | 11.9× | 3.4% | +27.9% |
| GH Research GHRS | United States | $1.25B | -19% | n/a | n/a | n/a | n/a | n/a |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.26B | -41% | -24% | -51% | 522.3× | n/a | n/a |
| C.Q. Pharmaceutical 000950.SZ | China | $1.24B | -27% | -3% | 1% | 18.6× | n/a | n/a |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.24B | -53% | n/a | n/a | n/a | n/a | n/a |
| Amphastar Pharmaceuticals AMPH | United States | $1.27B | +64% | +3% | 19% | 9.1× | 2.5% | +15.5% |
| Avalyn Pharma AVLN | United States | $1.23B | -1% | n/a | n/a | n/a | n/a | n/a |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.23B | -10% | -29% | 3% | 21.3× | 7.0% | -5.3% |
| Idorsia IDIA.SW | Switzerland | $1.22B | -9% | -5% | -70% | n/a | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.28B | -1% | +8% | 11% | 17.7× | -0.4% | -1.3% |
| D&D Pharmatech 347850.KS | South Korea | $1.22B | -49% | -77% | -2,324% | n/a | n/a | n/a |
| Harrow HROW | United States | $1.21B | +4% | +21% | 1% | 26.8× | n/a | n/a |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.30B | -24% | +2% | -2% | 60.7× | n/a | n/a |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.21B | -22% | +117% | -89% | n/a | n/a | n/a |
| LB Pharmaceuticals LBRX | United States | $1.30B | +43% | n/a | n/a | n/a | n/a | n/a |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.21B | +26% | -6% | -19% | n/a | 44.1% | -13.2% |
| Mabwell (Shanghai) Bioscience 2493.HK | Hong Kong | $1.20B | -29% | +21% | -127% | n/a | n/a | n/a |
| Ocular Therapeutix OCUL | United States | $1.31B | -26% | -10% | -681% | n/a | n/a | n/a |
| Innoviva INVA | United States | $1.31B | -17% | +12% | 38% | 9.5× | -17.2% | +3.9% |
| MannKind MNKD | United States | $1.31B | +25% | +32% | -2% | 174.4× | n/a | n/a |
| Windward Bio WWB | United States | $1.31B | n/a | n/a | n/a | n/a | n/a | n/a |